Company intelligence / Profile preview
Alkermes
Dublin, Irelandalkermes.com ↗
- Ownership
- Public · ALKS
- Employees
- ~1800
- Development stage
- Commercial
01
Overview
Alkermes has four approved drugs on the market for psychiatric and addiction indications. Its late-stage pipeline includes a pediatric formulation of olanzapine/samidorphan in Phase 3 for schizophrenia/bipolar I disorder and an orexin agonist program (ALKS 2680) in Phase 2 for sleep disorders. Additional preclinical programs target central nervous system diseases. The company recently divested its oncology business to focus on neuroscience.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculesextended-release injectablesoral drugs
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
Request access →03
Partnerships
Novo Nordisk (sale of manufacturing facility)previously with Janssen/J&J for RISPERDAL CONSTA®
04
Financials
- Market cap
- $7.7B
- Total revenue
- $496M
- Enterprise value
- $8.7B
Beyond the preview
Go deeper on Alkermes.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alkermes.